Diligence memo · auto-generated · as of July 2, 2026
Contro
Contro looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Contro operates in Healthtech, based in Africa. SA e-health platform Contro closes oversubscribed $585k pre-seed funding round 0 By Tom Jackson on November 14, 2022 News , Southern Africa South Africa’s Contro, a telehealth startup that focuses on sexual health and confidence treatment services, has announced the close of an oversubscribed pre-seed funding round, raising a total of ZAR10.1 million (US$585,000). Launched in May 2021, Contro offers subscription services for birth control, erectile dysfunction treatment, and hair loss treatment, as well as one-off treatment for STIs, Thrush and UTIs.
Sub-sector tags: healthtech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Contro has raised $585K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $585K on 2022-11-14.
Most recent recorded round closed around 2022-11-14.
Valuation (modeled)modeled
Provath models Contro at approximately $5.9M (range $367K–$33M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.13× the median modeled value of Pre-Seed Healthtech companies in 2022–2024 (174 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 3.6 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 22% of Healthtech peers (2138 compared).
Modeled value ranks above 25% of those peers.
Closest niche peers: Hoy Health Corp, Ennova Health LLC, Telebelly Health, Inc., Health Rosetta Group PBC, B2M Medical, Inc..
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.